Elvira Dolores FernÃ;ndez GirÃ;ldez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/113013/publications.pdf

Version: 2024-02-01

80 papers 3,555 citations

147801 31 h-index 58 g-index

81 all docs

81 docs citations

81 times ranked

4751 citing authors

#	Article	IF	Citations
1	High Incidence of Adverse Outcomes in Haemodialysis Patients with Diabetes with or without Diabetic Foot Syndrome: A 5-Year Observational Study in Lleida, Spain. Journal of Clinical Medicine, 2021, 10, 1368.	2.4	2
2	Mediterranean diet, physical activity and subcutaneous advanced glycation end-products' accumulation: a cross-sectional analysis in the ILERVAS project. European Journal of Nutrition, 2020, 59, 1233-1242.	3.9	17
3	Are Obesity Indices Useful for Detecting Subclinical Atheromatosis in a Middle-Aged Population?. Obesity Facts, 2020, 13, 29-39.	3.4	8
4	Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2019, 34, 2079-2088.	0.7	11
5	Lung function measurements in the prediabetes stage: data from the ILERVAS Project. Acta Diabetologica, 2019, 56, 1005-1012.	2.5	11
6	The influence of sleep apnea syndrome and intermittent hypoxia in carotid adventitial vasa vasorum. PLoS ONE, 2019, 14, e0211742.	2.5	6
7	Influence of Morbid Obesity and Bariatric Surgery Impact on the Carotid Adventitial Vasa Vasorum Signal. Obesity Surgery, 2018, 28, 3935-3942.	2.1	5
8	A Convolutional Neural Network for Automatic Characterization of Plaque Composition in Carotid Ultrasound. IEEE Journal of Biomedical and Health Informatics, 2017, 21, 48-55.	6.3	156
9	High Levels of Hemoglobin Promote Carotid Adventitial Vasa Vasorum Neoangiogenesis in Chronic Kidney Disease. Mediators of Inflammation, 2017, 2017, 1-11.	3.0	5
10	Calcium Phosphate Product Is Associated with Subclinical Carotid Atherosclerosis in Type 2 Diabetes. Journal of Diabetes Research, 2017, 2017, 1-8.	2.3	9
11	Preclinical carotid atherosclerosis in patients with latent autoimmune diabetes in adults (LADA), type 2 diabetes and classical type 1 diabetes. Cardiovascular Diabetology, 2017, 16, 94.	6.8	20
12	Effects of the Administration of 25(OH) Vitamin D3 in an Experimental Model of Chronic Kidney Disease in Animals Null for 1-Alpha-Hydroxylase. PLoS ONE, 2017, 12, e0170654.	2.5	8
13	Skin Autofluorescence and Subclinical Atherosclerosis in Mild to Moderate Chronic Kidney Disease: A Case-Control Study. PLoS ONE, 2017, 12, e0170778.	2.5	15
14	Prevalence of Diabetic Foot Disease in Patients with Diabetes Mellitus under Renal Replacement Therapy in Lleida, Spain. BioMed Research International, 2016, 2016, 1-8.	1.9	17
15	Subclinical Carotid Atherosclerosis in Asymptomatic Subjects With Type 2 Diabetes Mellitus. Journal of Cardiovascular Nursing, 2016, 31, E1-E7.	1.1	11
16	Vascular Calcification Induced by Chronic Kidney Disease Is Mediated by an Increase of 1α-Hydroxylase Expression in Vascular Smooth Muscle Cells. Journal of Bone and Mineral Research, 2016, 31, 1865-1876.	2.8	28
17	Diálisis peritoneal incremental: resultados clÃnicos y preservación de la función renal residual. Nefrologia, 2016, 36, 299-303.	0.4	11
18	Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study. Nephrology Dialysis Transplantation, 2016, 32, gfw039.	0.7	28

#	Article	IF	CITATIONS
19	Estudio de intervenci $ ilde{A}^3$ n aleatorizado para evaluar la prevalencia de enfermedad ateromatosa y renal ocultas y su impacto en la morbimortalidad: Proyecto ILERVAS. Nefrologia, 2016, 36, 389-396.	0.4	20
20	Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease. Atherosclerosis, 2016, 253, 135-143.	0.8	33
21	Increased Burden of Cerebral Small Vessel Disease in Patients With Type 2 Diabetes and Retinopathy. Diabetes Care, 2016, 39, 1614-1620.	8.6	55
22	Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 287-296.	4.5	54
23	Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 413-422.	4.5	19
24	FP359SUBCLINICAL PERIPHERAL ARTERY DISEASE PREDICTS CARDIOVASCULAR EVENTS IN CHRONIC RENAL IMPAIRMENT: THE NEFRONA PROJECT. Nephrology Dialysis Transplantation, 2015, 30, iii188-iii189.	0.7	0
25	SP357PROGRESSION OF PERIPHERAL ARTERY DISEASE IN CHRONIC RENAL IMPAIRMENT: THE NEFRONA PROJECT. Nephrology Dialysis Transplantation, 2015, 30, iii497-iii497.	0.7	O
26	Microangiopathy of common carotid vasa vasorum in type 1 diabetes mellitus. Atherosclerosis, 2015, 241, 334-338.	0.8	12
27	Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases. Atherosclerosis, 2015, 239, 358-363.	0.8	15
28	Parathyroid-specific epidermal growth factor-receptor inactivation prevents uremia-induced parathyroid hyperplasia in mice. Nephrology Dialysis Transplantation, 2015, 30, 434-440.	0.7	21
29	Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrology Dialysis Transplantation, 2015, 30, 1176-1185.	0.7	85
30	Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease. Atherosclerosis, 2015, 242, 37-44.	0.8	23
31	Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference. Atherosclerosis, 2015, 241, 264-270.	0.8	35
32	Type 2 diabetes-associated carotid plaque burden is increased in patients with retinopathy compared to those without retinopathy. Cardiovascular Diabetology, 2015, 14, 33.	6.8	47
33	Left carotid adventitial vasa vasorum signal correlates directly with age and with left carotid intima-media thickness in individuals without atheromatous risk factors. Cardiovascular Ultrasound, 2015, 13, 20.	1.6	16
34	The induction of C/EBPÂ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease. Nephrology Dialysis Transplantation, 2015, 30, 423-433.	0.7	29
35	Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. PLoS ONE, 2015, 10, e0136863.	2.5	51
36	Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrology, 2014, 15, 168.	1.8	51

#	Article	IF	CITATIONS
37	High phosphate diet increases arterial blood pressure via a parathyroid hormone mediated increase of renin. Journal of Hypertension, 2014, 32, 1822-1832.	0.5	35
38	Lack of vitamin D receptor causes stress-induced premature senescence in vascular smooth muscle cells through enhanced local angiotensin-II signals. Atherosclerosis, 2014, 235, 247-255.	0.8	51
39	Prevalence of subclinical atheromatosis and associated risk factors in chronic kidney disease: the NEFRONA study. Nephrology Dialysis Transplantation, 2014, 29, 1415-1422.	0.7	74
40	Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma. Laboratory Investigation, 2014, 94, 608-622.	3.7	27
41	A lower proportion of circulating active parathyroid hormone in peritoneal dialysis does not allow the pth inter-method adjustment proposed for haemodialysis. Nefrologia, 2014, 34, 330-40.	0.4	7
42	A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients. BMC Nephrology, 2013, 14, 221.	1.8	26
43	Microangiopathy of large artery wall: A neglected complication ofÂdiabetes mellitus. Atherosclerosis, 2013, 228, 142-147.	0.8	28
44	Pseudo-enhancement does not explain the increased carotid adventitial vasa vasorum signal in diabetic patients. Atherosclerosis, 2013, 229, 459-461.	0.8	5
45	The Role of Carotid Ultrasound in Assessing Carotid Atherosclerosis in Individuals at Low-to-intermediate Cardiovascular Risk. Revista Espanola De Cardiologia (English Ed), 2013, 66, 929-934.	0.6	13
46	Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. Journal of Nephrology, 2013, 26, 1105-1113.	2.0	22
47	Are the K/DOQI objectives for bone mineral alterations in stage 3-5 chronic kidney disease patients unreachable or inadequate?. Nefrologia, 2013, 33, 1-6.	0.4	42
48	Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. American Journal of Physiology - Renal Physiology, 2012, 302, F647-F657.	2.7	150
49	Assessment of the Potential Role of Active Vitamin D Treatment in Telomere Length: A Case–Control Study in Hemodialysis Patients. Clinical Therapeutics, 2012, 34, 849-856.	2,5	25
50	Glutamatergic Signaling Maintains the Epithelial Phenotype of Proximal Tubular Cells. Journal of the American Society of Nephrology: JASN, 2011, 22, 1099-1111.	6.1	43
51	Large Artery Calcification on Dialysis Patients Is Located in the Intima and Related to Atherosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 303-310.	4.5	63
52	Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.NM.B.D.). Nefrologia, 2011, 31 Suppl 1, 3-32.	0.4	37
53	Sustained activation of renal <i>N</i> -methyl- <scp>d</scp> -aspartate receptors decreases vitamin D synthesis: a possible role for glutamate on the onset of secondary HPT. American Journal of Physiology - Endocrinology and Metabolism, 2010, 299, E825-E831.	3.5	18
54	Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrology, 2010, 11, 14.	1.8	72

#	Article	IF	CITATIONS
55	Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrology Dialysis Transplantation, 2010, 25, 3017-3025.	0.7	50
56	Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease. Kidney International, 2010, 78, 1275-1280.	5.2	37
57	RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4–Dependent Pathway. Circulation Research, 2009, 104, 1041-1048.	4.5	205
58	<i>N</i> -methyl- <scp>d</scp> -aspartate receptors are expressed in rat parathyroid gland and regulate PTH secretion. American Journal of Physiology - Renal Physiology, 2009, 296, F1291-F1296.	2.7	21
59	A new role for vitamin D receptor activation in chronic kidney disease. American Journal of Physiology - Renal Physiology, 2009, 297, F1502-F1509.	2.7	32
60	Vitamin D and the vasculature: can we teach an old drug new tricks?. Expert Opinion on Therapeutic Targets, 2009, 13, 29-38.	3.4	20
61	1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis, 2009, 204, 85-89.	0.8	151
62	Vitamin D receptor levels in colorectal cancer. Journal of Steroid Biochemistry and Molecular Biology, 2008, 111, 87-90.	2.5	18
63	Mineral metabolism parameters throughout chronic kidney disease stages 1-5achievement of K/DOQI target ranges. Nephrology Dialysis Transplantation, 2007, 22, 1171-1176.	0.7	219
64	Differential Effects of Vitamin D Analogs on Vascular Calcification. Journal of Bone and Mineral Research, 2007, 22, 860-866.	2.8	150
65	Vitamin D receptor polymorphisms and diseases. Clinica Chimica Acta, 2006, 371, 1-12.	1.1	409
66	Haemoperitoneum caused by bilateral renal cyst rupture in an ACKD peritoneal dialysis patient. Nephrology Dialysis Transplantation, 2006, 21, 789-791.	0.7	22
67	A Forgotten Method to Induce Experimental Chronic Renal Failure in the Rat by Ligation of the Renal Parenchyma. Nephron Experimental Nephrology, 2006, 103, e126-e130.	2.2	18
68	Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney International, 2003, 63, S111-S114.	5. 2	94
69	Overview of renal bone disease: Causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach. Kidney International, 2003, 64, S113-S119.	5.2	15
70	Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. Journal of Hypertension, 2003, 21, 2069-75.	0.5	21
71	Is vitamin D receptor gene polymorphism an independent predictor of mortality in hemodialysis patients?: In Reply. American Journal of Kidney Diseases, 2002, 39, 442.	1.9	0
72	Rapid decline in renal function reflects reversibility and predicts the outcome after angioplasty in renal artery stenosis. American Journal of Kidney Diseases, 2002, 39, 60-66.	1.9	141

#	Article	IF	CITATIONS
73	Influence of vitamin D receptor gene polymorphisms on mortality risk in hemodialysis patients. American Journal of Kidney Diseases, 2001, 38, 965-974.	1.9	45
74	Host Genetic Background at CCR5 Chemokine Receptor and Vitamin D Receptor Loci and Human Immunodeficiency Virus (HIV) Type 1 Disease Progression among HIVâ€Seropositive Injection Drug Users. Journal of Infectious Diseases, 2001, 184, 1279-1288.	4.0	50
75	Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient. Kidney International, 1999, 56, 306-317.	5.2	38
76	Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients. Kidney International, 1999, 56, 1349-1353.	5.2	39
77	Grover's disease in patients with chronic renal failure receiving hemodialysis: Clinicopathologic review of 4 cases. Journal of the American Academy of Dermatology, 1999, 41, 1029-1033.	1.2	31
78	Cocaine-induced acute renal failure without rhabdomyolysis. Nephrology Dialysis Transplantation, 1999, 14, 2970-2971.	0.7	19
79	Evidence for Both Abnormal Set Point of PTH Stimulation by Calcium and Adaptation to Serum Calcium in Hemodialysis Patients with Hyperparathyroidism. Journal of Bone and Mineral Research, 1997, 12, 347-355.	2.8	34
80	Dialysis-Associated Amyloidosis Presenting as a Tumour. Nephrology Dialysis Transplantation, 1990, 5, 237-237.	0.7	4